To further explore the effect of PKM2 in KRAS mutant cancer cells, time course simulations were carried out where either PKM2 or c-Myc were systematically downregulated in cancer, while they were separately up-regulated in physiological conditions (Figure 2). The gene discussed is KRAS; the disease is cancer.